IPO Calendar
Lead Manager
- J P Morgan Chase (515)
- Goldman Sachs (492)
- Morgan Stanley (445)
- Bank of America Merrill Lynch (374)
- Citigroup (236)
- Jefferies (223)
- Credit Suisse (180)
- Barclays (158)
- Cowen and Company (147)
- Deutsche Bank (85)
- Leerink Partners (73)
- Piper Jaffray (70)
- Stifel (67)
- UBS Investment Bank (56)
- Evercore (55)
- RBC Capital (53)
- BMO Capital (52)
- Wells Fargo (48)
- Piper Sandler (43)
- Revere Securities (42)
More +
IPO - Pricing (8)
Leerink Partners
| UnderWriters* | |||||||||||
| Date | Company Name | Sector | Price ($) |
Size (M) |
1 | 2 | 3 | Rank | Turnover | Gain | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 11 | WAVE Life Scien | Health-Care | 16 | 6 | JEFF | LRNK | 21.4% | 0% | |||
| Nov 5 | Kura Oncology I | Health-Care | 8 | 6 | CITI | LRNK | 12.6% | -2% | |||
| Sep 18 | Nabriva Therape | Health-Care | 10.3 | 9 | LRNK | RBC | 21.2% | 29.2% | |||
| May 6 | HTG Molecular D | Capital-Goods | 14 | 3 | LRNK | 25.4% | -1.6% | ||||
| May 6 | Adaptimmune The | Health-Care | 17 | 11 | BAML | COWN | LRNK | 73.8% | -5.9% | ||
| Apr 15 | Cidara Therapeu | Health-Care | 16 | 4 | JEFF | LRNK | 94% | 0% | |||
| Feb 13 | Bellerophon The | Health-Care | 12 | 5 | COWN | LRNK | 30.6% | -25.3% | |||
| Jan 28 | Ascendis Pharma | Health-Care | 18 | 6 | BAML | LRNK | 58.5% | 4.6% | |||
*
Lead manager or one of top three managers in an underwriting team.